Welcome to Medications.com

Metoprolol Succinate ER Information

What's inside Metoprolol Succinate ER

Metoprolol Succinate ER Active Ingredients: metoprolol succinate, details.
Metoprolol Succinate ER Dosages & Strengths
Strength Format Route Strength Class
Metoprolol Succinate ER 25 mg tablet, extended release oral 1.0 each OTC

Recent Metoprolol Succinate ER Side Effects

Posted by zadwit about 1 month ago
10/26/2009 I was on Metoprolol ER 50mg daily for two years. started to wake up at night short of breath, rapid hear rate (11...

Posted by loreese about 1 month ago
OMG..My Dr prescribed Metoprolol yesterday. I took the first one this morning(before reading about it). Is there anything go...

Posted by genedell 2 months ago
I am 43 and have now been on 4 different medications for HBP over the last 8 months. I have never taken pills regularly befor...


Metoprolol Succinate ER in the News

Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results - Earthtimes
The third quarter 2007 launch of three additional strengths of metoprolol succinate ER (50mg, 100mg, and 200mg), coupled with the fourth quarter 2006 launch ...
Fri Feb 29 17:12:58 -0500 2008

Par Pharmaceutical Reports Third-Quarter 2007 Results - PR Newswire (press release)
The third quarter launch of three additional strengths of metoprolol succinate ER (50mg, 100mg, and 200mg), coupled with the fourth quarter 2006 launch of ...
Thu Dec 20 09:09:02 -0500 2007

Par Pharmaceutical Reports Third-Quarter 2007 Results - CNNMoney.com
The third quarter launch of three additional strengths of metoprolol succinate ER (50mg, 100mg, and 200mg), coupled with the fourth quarter 2006 launch of ...
Thu Dec 20 06:06:35 -0500 2007


Metoprolol Succinate ER Chemical Information

metoprolol succinate - The succinate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol succinate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea